Nuclear Medicine Market by Product (Diagnostic Medicine, Therapeutic Medicine); by Applications (Diagnostic Application, Therapeutic Application); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Rest of the World) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018-2026
Industry Trends
Nuclear medicines are radioactive materials called radiotracers that are injected into the bloodstream, inhaled or swallowed. It is used in diagnosis of various diseases. The radiotracer travels through the area to be examined and the energy released from these radiotracers in the form of gamma rays are detected by a special camera and a computer. Nuclear medicine imaging helps to collect unique information that often cannot be obtained using other imaging techniques and offers the scope to identify disease in its earliest stages. The nuclear medicine market, in terms of revenue, was valued at US$ 4.62 Bn in 2016 and is expected to reach US$ 6.81 Bn by 2021.
Nuclear Medicine Market, By Product Type, 2018-2026 (US$ Billion)
Nuclear Medicine Market, by Product Type
Global market based on the product type is classified as diagnostic medicine and therapeutic medicine. In the diagnosis, there are two types of imaging techniques which includes, single-photon emission computed tomography (SPECT) and positron emission tomography (PET). These techniques are very helpful in diagnosis of gall bladder disease, thyroid disease, cancer, Alzheimer's disease, heart conditions and brain conditions. The diagnostic medicine held the largest share in global nuclear medicine market and is also anticipated to be the fastest growing market in terms of the CAGR. The growing importance of diagnosis of fatal diseases among people, has driven the diagnostic medicine segment.
Nuclear Medicine Market, by Region
In the global market, North America is expected to be the leading market during the forecast period. The United States has shown substantial growth in the North America region. This growth is mainly attributed to the advancement in technology such as the development of molecular imaging based on the tracer principle, the introduction of new radiopharmaceuticals for diagnosis and therapy and hybrid imaging. The Europe and Asia Pacific areas account for noteworthy shares in the nuclear medicine market.
Competitive Market Share
The report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions(M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.
Some of the key participants of global nuclear medicine market are Cardinal Health, Inc., Medtronic, Minimally Invasive Therapies, Ion Beam Applications S.A (IBA Worldwide), Lantheus Medical Imaging Inc., General Electric Company, Bracco Imaging S.p.A, Bayer AG, Advanced Medical Isotope Corporation, Alliance Medical Limited, Alseres Pharmaceuticals, Inc., Avid Radiopharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Immunomedics, Inc., Jubilant Pharma LLC, Mallinckrodt Pharmaceuticals, Medi-Radiopharma Co., Ltd., Peregrine Pharmaceuticals, Inc. and Positron Corporation, Nordion (Canada) Inc. amongst others.
Nuclear Medicine Industry Background
1. Introduction
1.1. Market Scope
1.2. Market Segmentation
1.3. Methodology
1.4. Assumptions
2. Nuclear
Medicine Market Snapshot
3. Executive
Summary: Nuclear Medicine Market
4. Qualitative
Analysis: Nuclear Medicine Market
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Development
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Trends in Market
5. Global
Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
5.1. Overview
5.1.1. Global Market Revenue (US$ Mn) and Forecasts
5.2. Global Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Product
5.2.1. Diagnostic Medicine (Definition, Market
Penetration, Market Revenue Expected to Increase by 2026, Compound Annual
Growth Rate (CAGR) and information on SPECT Radiopharmaceutical, PET
Radiopharmaceutical)
5.2.1.1.
SPECT
Radiopharmaceutical
5.2.1.2.
PET
Radiopharmaceutical
5.2.2. Therapeutic Medicine (Definition, Market
Penetration, Market Revenue Expected to Increase by 2026, Compound Annual
Growth Rate (CAGR) and information on Beta Emitters, Alpha Emitters,
Brachytherapy Isotopes)
5.2.2.1.
Beta Emitters
5.2.2.2.
Alpha Emitters
5.2.2.3.
Brachytherapy
Isotopes
5.3. Key Segment for Channeling Investments
5.3.1. By Product
6. Global
Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
6.1. Overview
6.2. Global Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Applications
6.2.1. Diagnostic Application (Definition, Market
Penetration, Market Revenue Expected to Increase by 2026, Compound Annual
Growth Rate (CAGR) and information on Oncology, Cardiology, Neurology, Others)
6.2.1.1.
Oncology
6.2.1.2.
Cardiology
6.2.1.3.
Neurology
6.2.1.4.
Others
6.2.2. Therapeutic Application (Definition, Market
Penetration, Market Revenue Expected to Increase by 2026, Compound Annual
Growth Rate (CAGR) and information on Thyroid, Bone Metastasis, Lymphoma,
Endocrine Tumors, Others)
6.2.2.1.
Thyroid
6.2.2.2.
Bone Metastasis
6.2.2.3.
Lymphoma
6.2.2.4.
Endocrine
Tumors
6.2.2.5.
Others
6.3. Key Segment for Channeling Investments
6.3.1. By Applications
7. North
America Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
7.1. Overview
7.1.1. North America Market Revenue (US$ Mn)
7.2. North America Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Product
7.2.1. Diagnostic Medicine
7.2.1.1.
SPECT
Radiopharmaceutical
7.2.1.2.
PET Radiopharmaceutical
7.2.2. Therapeutic Medicine
7.2.2.1.
Beta Emitters
7.2.2.2.
Alpha Emitters
7.2.2.3.
Brachytherapy
Isotopes
7.3. North America Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Applications
7.3.1. Diagnostic Application
7.3.1.1.
Oncology
7.3.1.2.
Cardiology
7.3.1.3.
Neurology
7.3.1.4.
Others
7.3.2. Therapeutic Application
7.3.2.1.
Thyroid
7.3.2.2.
Bone Metastasis
7.3.2.3.
Lymphoma
7.3.2.4.
Endocrine
Tumors
7.3.2.5.
Others
7.4. North America Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Country
7.4.1. U.S.
7.4.1.1.
U.S. Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
7.4.1.1.1. Diagnostic Medicine
7.4.1.1.1.1. SPECT Radiopharmaceutical
7.4.1.1.1.2. PET Radiopharmaceutical
7.4.1.1.2. Therapeutic Medicine
7.4.1.1.2.1. Beta Emitters
7.4.1.1.2.2. Alpha Emitters
7.4.1.1.2.3. Brachytherapy Isotopes
7.4.1.2.
U.S. Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
7.4.1.2.1. Diagnostic Application
7.4.1.2.1.1. Oncology
7.4.1.2.1.2. Cardiology
7.4.1.2.1.3. Neurology
7.4.1.2.1.4. Others
7.4.1.2.2. Therapeutic Application
7.4.1.2.2.1. Thyroid
7.4.1.2.2.2. Bone Metastasis
7.4.1.2.2.3. Lymphoma
7.4.1.2.2.4. Endocrine Tumors
7.4.1.2.2.5. Others
7.4.2. Rest of North America
7.4.2.1.
Rest of North
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
7.4.2.1.1. Diagnostic Medicine
7.4.2.1.1.1. SPECT Radiopharmaceutical
7.4.2.1.1.2. PET Radiopharmaceutical
7.4.2.1.2. Therapeutic Medicine
7.4.2.1.2.1. Beta Emitters
7.4.2.1.2.2. Alpha Emitters
7.4.2.1.2.3. Brachytherapy Isotopes
7.4.2.2.
Rest of North
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
7.4.2.2.1. Diagnostic Application
7.4.2.2.1.1. Oncology
7.4.2.2.1.2. Cardiology
7.4.2.2.1.3. Neurology
7.4.2.2.1.4. Others
7.4.2.2.2. Therapeutic Application
7.4.2.2.2.1. Thyroid
7.4.2.2.2.2. Bone Metastasis
7.4.2.2.2.3. Lymphoma
7.4.2.2.2.4. Endocrine Tumors
7.4.2.2.2.5. Others
7.5. Key Segment for Channeling Investments
7.5.1. By Country
7.5.2. By Product
7.5.3. By Applications
8. Europe
Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
8.1. Overview
8.1.1. Europe Market Revenue (US$ Mn)
8.2. Europe Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Product
8.2.1. Diagnostic Medicine
8.2.1.1.
SPECT
Radiopharmaceutical
8.2.1.2.
PET
Radiopharmaceutical
8.2.2. Therapeutic Medicine
8.2.2.1.
Beta Emitters
8.2.2.2.
Alpha Emitters
8.2.2.3.
Brachytherapy
Isotopes
8.3. Europe Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Applications
8.3.1. Diagnostic Application
8.3.1.1.
Oncology
8.3.1.2.
Cardiology
8.3.1.3.
Neurology
8.3.1.4.
Others
8.3.2. Therapeutic Application
8.3.2.1.
Thyroid
8.3.2.2.
Bone Metastasis
8.3.2.3.
Lymphoma
8.3.2.4.
Endocrine
Tumors
8.3.2.5.
Others
8.4. Europe Nuclear Medicine Market Revenue (US$ Mn)
and Forecasts, By Country
8.4.1. France
8.4.1.1.
France Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
8.4.1.1.1. Diagnostic Medicine
8.4.1.1.1.1. SPECT Radiopharmaceutical
8.4.1.1.1.2. PET Radiopharmaceutical
8.4.1.1.2. Therapeutic Medicine
8.4.1.1.2.1. Beta Emitters
8.4.1.1.2.2. Alpha Emitters
8.4.1.1.2.3. Brachytherapy Isotopes
8.4.1.2.
France Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
8.4.1.2.1. Diagnostic Application
8.4.1.2.1.1. Oncology
8.4.1.2.1.2. Cardiology
8.4.1.2.1.3. Neurology
8.4.1.2.1.4. Others
8.4.1.2.2. Therapeutic Application
8.4.1.2.2.1. Thyroid
8.4.1.2.2.2. Bone Metastasis
8.4.1.2.2.3. Lymphoma
8.4.1.2.2.4. Endocrine Tumors
8.4.1.2.2.5. Others
8.4.2. The UK
8.4.2.1.
The UK Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
8.4.2.1.1. Diagnostic Medicine
8.4.2.1.1.1. SPECT Radiopharmaceutical
8.4.2.1.1.2. PET Radiopharmaceutical
8.4.2.1.2. Therapeutic Medicine
8.4.2.1.2.1. Beta Emitters
8.4.2.1.2.2. Alpha Emitters
8.4.2.1.2.3. Brachytherapy Isotopes
8.4.2.2.
The UK Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
8.4.2.2.1. Diagnostic Application
8.4.2.2.1.1. Oncology
8.4.2.2.1.2. Cardiology
8.4.2.2.1.3. Neurology
8.4.2.2.1.4. Others
8.4.2.2.2. Therapeutic Application
8.4.2.2.2.1. Thyroid
8.4.2.2.2.2. Bone Metastasis
8.4.2.2.2.3. Lymphoma
8.4.2.2.2.4. Endocrine Tumors
8.4.2.2.2.5. Others
8.4.3. Spain
8.4.3.1.
Spain Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
8.4.3.1.1. Diagnostic Medicine
8.4.3.1.1.1. SPECT Radiopharmaceutical
8.4.3.1.1.2. PET Radiopharmaceutical
8.4.3.1.2. Therapeutic Medicine
8.4.3.1.2.1. Beta Emitters
8.4.3.1.2.2. Alpha Emitters
8.4.3.1.2.3. Brachytherapy Isotopes
8.4.3.2.
Spain Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
8.4.3.2.1. Diagnostic Application
8.4.3.2.1.1. Oncology
8.4.3.2.1.2. Cardiology
8.4.3.2.1.3. Neurology
8.4.3.2.1.4. Others
8.4.3.2.2. Therapeutic Application
8.4.3.2.2.1. Thyroid
8.4.3.2.2.2. Bone Metastasis
8.4.3.2.2.3. Lymphoma
8.4.3.2.2.4. Endocrine Tumors
8.4.3.2.2.5. Others
8.4.4. Germany
8.4.4.1.
Germany Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
8.4.4.1.1. Diagnostic Medicine
8.4.4.1.1.1. SPECT Radiopharmaceutical
8.4.4.1.1.2. PET Radiopharmaceutical
8.4.4.1.2. Therapeutic Medicine
8.4.4.1.2.1. Beta Emitters
8.4.4.1.2.2. Alpha Emitters
8.4.4.1.2.3. Brachytherapy Isotopes
8.4.4.2.
Germany Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
8.4.4.2.1. Diagnostic Application
8.4.4.2.1.1. Oncology
8.4.4.2.1.2. Cardiology
8.4.4.2.1.3. Neurology
8.4.4.2.1.4. Others
8.4.4.2.2. Therapeutic Application
8.4.4.2.2.1. Thyroid
8.4.4.2.2.2. Bone Metastasis
8.4.4.2.2.3. Lymphoma
8.4.4.2.2.4. Endocrine Tumors
8.4.4.2.2.5. Others
8.4.5. Italy
8.4.5.1.
Italy Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
8.4.5.1.1. Diagnostic Medicine
8.4.5.1.1.1. SPECT Radiopharmaceutical
8.4.5.1.1.2. PET Radiopharmaceutical
8.4.5.1.2. Therapeutic Medicine
8.4.5.1.2.1. Beta Emitters
8.4.5.1.2.2. Alpha Emitters
8.4.5.1.2.3. Brachytherapy Isotopes
8.4.5.2.
Italy Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
8.4.5.2.1. Diagnostic Application
8.4.5.2.1.1. Oncology
8.4.5.2.1.2. Cardiology
8.4.5.2.1.3. Neurology
8.4.5.2.1.4. Others
8.4.5.2.2. Therapeutic Application
8.4.5.2.2.1. Thyroid
8.4.5.2.2.2. Bone Metastasis
8.4.5.2.2.3. Lymphoma
8.4.5.2.2.4. Endocrine Tumors
8.4.5.2.2.5. Others
8.4.6. Rest of Europe
8.4.6.1.
Rest of Europe
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
8.4.6.1.1. Diagnostic Medicine
8.4.6.1.1.1. SPECT Radiopharmaceutical
8.4.6.1.1.2. PET Radiopharmaceutical
8.4.6.1.2. Therapeutic Medicine
8.4.6.1.2.1. Beta Emitters
8.4.6.1.2.2. Alpha Emitters
8.4.6.1.2.3. Brachytherapy Isotopes
8.4.6.2.
Rest of Europe
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
8.4.6.2.1. Diagnostic Application
8.4.6.2.1.1. Oncology
8.4.6.2.1.2. Cardiology
8.4.6.2.1.3. Neurology
8.4.6.2.1.4. Others
8.4.6.2.2. Therapeutic Application
8.4.6.2.2.1. Thyroid
8.4.6.2.2.2. Bone Metastasis
8.4.6.2.2.3. Lymphoma
8.4.6.2.2.4. Endocrine Tumors
8.4.6.2.2.5. Others
8.5. Key Segment for Channeling Investments
8.5.1. By Country
8.5.2. By Product
8.5.3. By Applications
9. Asia
Pacific Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
9.1. Overview
9.1.1. Asia Pacific Market Revenue (US$ Mn)
9.2. Asia Pacific Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Product
9.2.1. Diagnostic Medicine
9.2.1.1.
SPECT
Radiopharmaceutical
9.2.1.2.
PET
Radiopharmaceutical
9.2.2. Therapeutic Medicine
9.2.2.1.
Beta Emitters
9.2.2.2.
Alpha Emitters
9.2.2.3.
Brachytherapy
Isotopes
9.3. Asia Pacific Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Applications
9.3.1. Diagnostic Application
9.3.1.1.
Oncology
9.3.1.2.
Cardiology
9.3.1.3.
Neurology
9.3.1.4.
Others
9.3.2. Therapeutic Application
9.3.2.1.
Thyroid
9.3.2.2.
Bone Metastasis
9.3.2.3.
Lymphoma
9.3.2.4.
Endocrine
Tumors
9.3.2.5.
Others
9.4. Asia Pacific Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Country
9.4.1. China
9.4.1.1.
China Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
9.4.1.1.1. Diagnostic Medicine
9.4.1.1.1.1. SPECT Radiopharmaceutical
9.4.1.1.1.2. PET Radiopharmaceutical
9.4.1.1.2. Therapeutic Medicine
9.4.1.1.2.1. Beta Emitters
9.4.1.1.2.2. Alpha Emitters
9.4.1.1.2.3. Brachytherapy Isotopes
9.4.1.2.
China Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
9.4.1.2.1. Diagnostic Application
9.4.1.2.1.1. Oncology
9.4.1.2.1.2. Cardiology
9.4.1.2.1.3. Neurology
9.4.1.2.1.4. Others
9.4.1.2.2. Therapeutic Application
9.4.1.2.2.1. Thyroid
9.4.1.2.2.2. Bone Metastasis
9.4.1.2.2.3. Lymphoma
9.4.1.2.2.4. Endocrine Tumors
9.4.1.2.2.5. Others
9.4.2. Japan
9.4.2.1.
Japan Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
9.4.2.1.1. Diagnostic Medicine
9.4.2.1.1.1. SPECT Radiopharmaceutical
9.4.2.1.1.2. PET Radiopharmaceutical
9.4.2.1.2. Therapeutic Medicine
9.4.2.1.2.1. Beta Emitters
9.4.2.1.2.2. Alpha Emitters
9.4.2.1.2.3. Brachytherapy Isotopes
9.4.2.2.
Japan Nuclear Medicine
Market Revenue (US$ Mn) and Forecasts, By Applications
9.4.2.2.1. Diagnostic Application
9.4.2.2.1.1. Oncology
9.4.2.2.1.2. Cardiology
9.4.2.2.1.3. Neurology
9.4.2.2.1.4. Others
9.4.2.2.2. Therapeutic Application
9.4.2.2.2.1. Thyroid
9.4.2.2.2.2. Bone Metastasis
9.4.2.2.2.3. Lymphoma
9.4.2.2.2.4. Endocrine Tumors
9.4.2.2.2.5. Others
9.4.3. India
9.4.3.1.
India Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
9.4.3.1.1. Diagnostic Medicine
9.4.3.1.1.1. SPECT Radiopharmaceutical
9.4.3.1.1.2. PET Radiopharmaceutical
9.4.3.1.2. Therapeutic Medicine
9.4.3.1.2.1. Beta Emitters
9.4.3.1.2.2. Alpha Emitters
9.4.3.1.2.3. Brachytherapy Isotopes
9.4.3.2.
India Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
9.4.3.2.1. Diagnostic Application
9.4.3.2.1.1. Oncology
9.4.3.2.1.2. Cardiology
9.4.3.2.1.3. Neurology
9.4.3.2.1.4. Others
9.4.3.2.2. Therapeutic Application
9.4.3.2.2.1. Thyroid
9.4.3.2.2.2. Bone Metastasis
9.4.3.2.2.3. Lymphoma
9.4.3.2.2.4. Endocrine Tumors
9.4.3.2.2.5. Others
9.4.4. Southeast Asia
9.4.4.1.
Southeast Asia
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
9.4.4.1.1. Diagnostic Medicine
9.4.4.1.1.1. SPECT Radiopharmaceutical
9.4.4.1.1.2. PET Radiopharmaceutical
9.4.4.1.2. Therapeutic Medicine
9.4.4.1.2.1. Beta Emitters
9.4.4.1.2.2. Alpha Emitters
9.4.4.1.2.3. Brachytherapy Isotopes
9.4.4.2.
Southeast Asia
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
9.4.4.2.1. Diagnostic Application
9.4.4.2.1.1. Oncology
9.4.4.2.1.2. Cardiology
9.4.4.2.1.3. Neurology
9.4.4.2.1.4. Others
9.4.4.2.2. Therapeutic Application
9.4.4.2.2.1. Thyroid
9.4.4.2.2.2. Bone Metastasis
9.4.4.2.2.3. Lymphoma
9.4.4.2.2.4. Endocrine Tumors
9.4.4.2.2.5. Others
9.4.5. Rest of Asia Pacific
9.4.5.1.
Rest of Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
9.4.5.1.1. Diagnostic Medicine
9.4.5.1.1.1. SPECT Radiopharmaceutical
9.4.5.1.1.2. PET Radiopharmaceutical
9.4.5.1.2. Therapeutic Medicine
9.4.5.1.2.1. Beta Emitters
9.4.5.1.2.2. Alpha Emitters
9.4.5.1.2.3. Brachytherapy Isotopes
9.4.5.2.
Rest of Asia
Pacific Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
9.4.5.2.1. Diagnostic Application
9.4.5.2.1.1. Oncology
9.4.5.2.1.2. Cardiology
9.4.5.2.1.3. Neurology
9.4.5.2.1.4. Others
9.4.5.2.2. Therapeutic Application
9.4.5.2.2.1. Thyroid
9.4.5.2.2.2. Bone Metastasis
9.4.5.2.2.3. Lymphoma
9.4.5.2.2.4. Endocrine Tumors
9.4.5.2.2.5. Others
9.5. Key Segment for Channeling Investments
9.5.1. By Country
9.5.2. By Product
9.5.3. By Applications
10. Middle
East and Africa Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
10.1. Overview
10.1.1. Middle East and Africa Market Revenue (US$ Mn)
10.2. Middle East and Africa Nuclear Medicine Market
Revenue (US$ Mn) and Forecasts, By Product
10.2.1. Diagnostic Medicine
10.2.1.1.
SPECT
Radiopharmaceutical
10.2.1.2.
PET
Radiopharmaceutical
10.2.2. Therapeutic Medicine
10.2.2.1.
Beta Emitters
10.2.2.2.
Alpha Emitters
10.2.2.3.
Brachytherapy
Isotopes
10.3. Middle East and Africa Nuclear Medicine Market
Revenue (US$ Mn) and Forecasts, By Applications
10.3.1. Diagnostic Application
10.3.1.1.
Oncology
10.3.1.2.
Cardiology
10.3.1.3.
Neurology
10.3.1.4.
Others
10.3.2. Therapeutic Application
10.3.2.1.
Thyroid
10.3.2.2.
Bone Metastasis
10.3.2.3.
Lymphoma
10.3.2.4.
Endocrine
Tumors
10.3.2.5.
Others
10.4. Middle East and Africa Nuclear Medicine Market
Revenue (US$ Mn) and Forecasts, By Country
10.4.1. GCC Countries
10.4.1.1.
GCC Countries
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
10.4.1.1.1. Diagnostic Medicine
10.4.1.1.1.1. SPECT Radiopharmaceutical
10.4.1.1.1.2. PET Radiopharmaceutical
10.4.1.1.2. Therapeutic Medicine
10.4.1.1.2.1. Beta Emitters
10.4.1.1.2.2. Alpha Emitters
10.4.1.1.2.3. Brachytherapy Isotopes
10.4.1.2.
GCC Countries
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
10.4.1.2.1. Diagnostic Application
10.4.1.2.1.1. Oncology
10.4.1.2.1.2. Cardiology
10.4.1.2.1.3. Neurology
10.4.1.2.1.4. Others
10.4.1.2.2. Therapeutic Application
10.4.1.2.2.1. Thyroid
10.4.1.2.2.2. Bone Metastasis
10.4.1.2.2.3. Lymphoma
10.4.1.2.2.4. Endocrine Tumors
10.4.1.2.2.5. Others
10.4.2. Southern Africa
10.4.2.1.
Southern Africa
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
10.4.2.1.1. Diagnostic Medicine
10.4.2.1.1.1. SPECT Radiopharmaceutical
10.4.2.1.1.2. PET Radiopharmaceutical
10.4.2.1.2. Therapeutic Medicine
10.4.2.1.2.1. Beta Emitters
10.4.2.1.2.2. Alpha Emitters
10.4.2.1.2.3. Brachytherapy Isotopes
10.4.2.2.
Southern Africa
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
10.4.2.2.1. Diagnostic Application
10.4.2.2.1.1. Oncology
10.4.2.2.1.2. Cardiology
10.4.2.2.1.3. Neurology
10.4.2.2.1.4. Others
10.4.2.2.2. Therapeutic Application
10.4.2.2.2.1. Thyroid
10.4.2.2.2.2. Bone Metastasis
10.4.2.2.2.3. Lymphoma
10.4.2.2.2.4. Endocrine Tumors
10.4.2.2.2.5. Others
10.4.3. Rest of MEA
10.4.3.1.
Rest of MEA
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
10.4.3.1.1. Diagnostic Medicine
10.4.3.1.1.1. SPECT Radiopharmaceutical
10.4.3.1.1.2. PET Radiopharmaceutical
10.4.3.1.2. Therapeutic Medicine
10.4.3.1.2.1. Beta Emitters
10.4.3.1.2.2. Alpha Emitters
10.4.3.1.2.3. Brachytherapy Isotopes
10.4.3.2.
Rest of MEA
Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
10.4.3.2.1. Diagnostic Application
10.4.3.2.1.1. Oncology
10.4.3.2.1.2. Cardiology
10.4.3.2.1.3. Neurology
10.4.3.2.1.4. Others
10.4.3.2.2. Therapeutic Application
10.4.3.2.2.1. Thyroid
10.4.3.2.2.2. Bone Metastasis
10.4.3.2.2.3. Lymphoma
10.4.3.2.2.4. Endocrine Tumors
10.4.3.2.2.5. Others
10.5. Key Segment for Channeling Investments
10.5.1. By Country
10.5.2. By Product
10.5.3. By Applications
11. Latin
America Nuclear Medicine Market Analysis and Forecasts, 2018 – 2026
11.1. Overview
11.1.1. Latin America Market Revenue (US$ Mn)
11.2. Latin America Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Product
11.2.1. Diagnostic Medicine
11.2.1.1.
SPECT
Radiopharmaceutical
11.2.1.2.
PET
Radiopharmaceutical
11.2.2. Therapeutic Medicine
11.2.2.1.
Beta Emitters
11.2.2.2.
Alpha Emitters
11.2.2.3.
Brachytherapy
Isotopes
11.3. Latin America Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Applications
11.3.1. Diagnostic Application
11.3.1.1.
Oncology
11.3.1.2.
Cardiology
11.3.1.3.
Neurology
11.3.1.4.
Others
11.3.2. Therapeutic Application
11.3.2.1.
Thyroid
11.3.2.2.
Bone Metastasis
11.3.2.3.
Lymphoma
11.3.2.4.
Endocrine
Tumors
11.3.2.5.
Others
11.4. Latin America Nuclear Medicine Market Revenue
(US$ Mn) and Forecasts, By Country
11.4.1. Brazil
11.4.1.1.
Brazil Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Product
11.4.1.1.1. Diagnostic Medicine
11.4.1.1.1.1. SPECT Radiopharmaceutical
11.4.1.1.1.2. PET Radiopharmaceutical
11.4.1.1.2. Therapeutic Medicine
11.4.1.1.2.1. Beta Emitters
11.4.1.1.2.2. Alpha Emitters
11.4.1.1.2.3. Brachytherapy Isotopes
11.4.1.2.
Brazil Nuclear
Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
11.4.1.2.1. Diagnostic Application
11.4.1.2.1.1. Oncology
11.4.1.2.1.2. Cardiology
11.4.1.2.1.3. Neurology
11.4.1.2.1.4. Others
11.4.1.2.2. Therapeutic Application
11.4.1.2.2.1. Thyroid
11.4.1.2.2.2. Bone Metastasis
11.4.1.2.2.3. Lymphoma
11.4.1.2.2.4. Endocrine Tumors
11.4.1.2.2.5. Others
11.4.2. Rest of Latin America
11.4.2.1.
Rest of Latin
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Product
11.4.2.1.1. Diagnostic Medicine
11.4.2.1.1.1. SPECT Radiopharmaceutical
11.4.2.1.1.2. PET Radiopharmaceutical
11.4.2.1.2. Therapeutic Medicine
11.4.2.1.2.1. Beta Emitters
11.4.2.1.2.2. Alpha Emitters
11.4.2.1.2.3. Brachytherapy Isotopes
11.4.2.2.
Rest of Latin
America Nuclear Medicine Market Revenue (US$ Mn) and Forecasts, By Applications
11.4.2.2.1. Diagnostic Application
11.4.2.2.1.1. Oncology
11.4.2.2.1.2. Cardiology
11.4.2.2.1.3. Neurology
11.4.2.2.1.4. Others
11.4.2.2.2. Therapeutic Application
11.4.2.2.2.1. Thyroid
11.4.2.2.2.2. Bone Metastasis
11.4.2.2.2.3. Lymphoma
11.4.2.2.2.4. Endocrine Tumors
11.4.2.2.2.5. Others
11.5. Key Segment for Channeling Investments
11.5.1. By Country
11.5.2. By Product
11.5.3. By Applications
12. Competitive
Benchmarking
12.1. Player Positioning Analysis
12.2. Global Presence and Growth Strategies
13. Player
Profiles
13.1. Cardinal Health, Inc.
13.1.1. Company Details
13.1.2. Company Overview
13.1.3. Product Offerings
13.1.4. Key Developments
13.1.5. Financial Analysis
13.1.6. SWOT Analysis
13.1.7. Business Strategies
13.2. Medtronic
13.2.1. Company Details
13.2.2. Company Overview
13.2.3. Product Offerings
13.2.4. Key Developments
13.2.5. Financial Analysis
13.2.6. SWOT Analysis
13.2.7. Business Strategies
13.3. Minimally Invasive Therapies
13.3.1. Company Details
13.3.2. Company Overview
13.3.3. Product Offerings
13.3.4. Key Developments
13.3.5. Financial Analysis
13.3.6. SWOT Analysis
13.3.7. Business Strategies
13.4. Ion Beam Applications S.A (IBA Worldwide)
13.4.1. Company Details
13.4.2. Company Overview
13.4.3. Product Offerings
13.4.4. Key Developments
13.4.5. Financial Analysis
13.4.6. SWOT Analysis
13.4.7. Business Strategies
13.5. Lantheus Medical Imaging Inc.
13.5.1. Company Details
13.5.2. Company Overview
13.5.3. Product Offerings
13.5.4. Key Developments
13.5.5. Financial Analysis
13.5.6. SWOT Analysis
13.5.7. Business Strategies
13.6. General Electric Company
13.6.1. Company Details
13.6.2. Company Overview
13.6.3. Product Offerings
13.6.4. Key Developments
13.6.5. Financial Analysis
13.6.6. SWOT Analysis
13.6.7. Business Strategies
13.7. Bracco Imaging S.p.A
13.7.1. Company Details
13.7.2. Company Overview
13.7.3. Product Offerings
13.7.4. Key Developments
13.7.5. Financial Analysis
13.7.6. SWOT Analysis
13.7.7. Business Strategies
13.8. Bayer AG
13.8.1. Company Details
13.8.2. Company Overview
13.8.3. Product Offerings
13.8.4. Key Developments
13.8.5. Financial Analysis
13.8.6. SWOT Analysis
13.8.7. Business Strategies
13.9. Advanced Medical Isotope Corporation
13.9.1. Company Details
13.9.2. Company Overview
13.9.3. Product Offerings
13.9.4. Key Developments
13.9.5. Financial Analysis
13.9.6. SWOT Analysis
13.9.7. Business Strategies
13.10. Alliance Medical Limited
13.10.1. Company Details
13.10.2. Company Overview
13.10.3. Product Offerings
13.10.4. Key Developments
13.10.5. Financial Analysis
13.10.6. SWOT Analysis
13.10.7. Business Strategies
13.11. Alseres Pharmaceuticals, Inc.
13.11.1. Company Details
13.11.2. Company Overview
13.11.3. Product Offerings
13.11.4. Key Developments
13.11.5. Financial Analysis
13.11.6. SWOT Analysis
13.11.7. Business Strategies
13.12. Avid Radiopharmaceuticals, Inc.
13.12.1. Company Details
13.12.2. Company Overview
13.12.3. Product Offerings
13.12.4. Key Developments
13.12.5. Financial Analysis
13.12.6. SWOT Analysis
13.12.7. Business Strategies
13.13. Actinium Pharmaceuticals, Inc.
13.13.1. Company Details
13.13.2. Company Overview
13.13.3. Product Offerings
13.13.4. Key Developments
13.13.5. Financial Analysis
13.13.6. SWOT Analysis
13.13.7. Business Strategies
13.14. Immunomedics, Inc.
13.14.1. Company Details
13.14.2. Company Overview
13.14.3. Product Offerings
13.14.4. Key Developments
13.14.5. Financial Analysis
13.14.6. SWOT Analysis
13.14.7. Business Strategies
13.15. Jubilant Pharma LLC
13.15.1. Company Details
13.15.2. Company Overview
13.15.3. Product Offerings
13.15.4. Key Developments
13.15.5. Financial Analysis
13.15.6. SWOT Analysis
13.15.7. Business Strategies
13.16. Mallinckrodt Pharmaceuticals
13.16.1. Company Details
13.16.2. Company Overview
13.16.3. Product Offerings
13.16.4. Key Developments
13.16.5. Financial Analysis
13.16.6. SWOT Analysis
13.16.7. Business Strategies
13.17. Medi-Radiopharma Co., Ltd.
13.17.1. Company Details
13.17.2. Company Overview
13.17.3. Product Offerings
13.17.4. Key Developments
13.17.5. Financial Analysis
13.17.6. SWOT Analysis
13.17.7. Business Strategies
13.18. Nordion (Canada) Inc.
13.18.1. Company Details
13.18.2. Company Overview
13.18.3. Product Offerings
13.18.4. Key Developments
13.18.5. Financial Analysis
13.18.6. SWOT Analysis
13.18.7. Business Strategies
13.19. Peregrine Pharmaceuticals, Inc.
13.19.1. Company Details
13.19.2. Company Overview
13.19.3. Product Offerings
13.19.4. Key Developments
13.19.5. Financial Analysis
13.19.6. SWOT Analysis
13.19.7. Business Strategies
13.20. Positron Corporation
13.20.1. Company Details
13.20.2. Company Overview
13.20.3. Product Offerings
13.20.4. Key Developments
13.20.5. Financial Analysis
13.20.6. SWOT Analysis
13.20.7. Business Strategies
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.